βIII-Tubulin: biomarker of taxane resistance or drug target? (Q28284878)

Europe PubMed Central

title

βIII-Tubulin: biomarker of taxane resistance or drug target? (English)

0 references

0 references

6

0 references

Giovanni Scambia

5

0 references

Marisa Mariani

2

0 references

Cristiano Ferlini

object named as

Cristiano Ferlini

7

0 references

author name string

Roshan Karki

1

0 references

Mirko Andreoli

3

0 references

Shiquan He

Expert Opinion on Therapeutic Targets

4

0 references

language of work or name

English

0 references

publication date

April 2013

0 references

published in

0 references

volume

17

0 references

issue

4

0 references

page(s)

461-72

0 references

cites work

Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Tubulins as therapeutic targets in cancer: from bench to bedside

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Class III &#946; -Tubulin (TUBB3): More than a Biomarker in Solid Tumors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Tubulin proteomics: towards breaking the code.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Effects of FSH on testicular mRNA transcript levels in the hypogonadal mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Class III β‐tubulin in human development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

How do microtubule-targeted drugs work? An overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

HuR regulates beta-tubulin isotype expression in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Molecular mechanisms of patupilone resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Specific β-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Current status and future prospects of chemotherapy for metastatic gastric cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Gender influences the class III and V β-tubulin ability to predict poor outcome in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

A common promotor variant in the cytochrome P450c17alpha (CYP17) gene is associated with bioavailability testosterone levels and bone size in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Expression of CYP19 and CYP17 is associated with leg length, weight, and BMI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Increased expression of class III beta-tubulin in castration-resistant human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Expression of ERCC1, p53, and class III β-tubulin do not reveal chemoresistance in endometrial cancer: results from an immunohistochemical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Updates in therapy for uterine serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Loss of class III beta-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Immunohistochemical study of HER2 and TUBB3 proteins in extramammary Paget disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Tumoral and tissue-specific expression of the major human beta-tubulin isotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Novel drugs targeting microtubules: the role of epothilones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Hedgehog signal transduction: signal integration and cross talk in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Gli family transcription factors are drivers of patupilone resistance in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

Class III -Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2013.766170

10.1517/14728222.2013.766170

21 January 2018

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

23379899

1 reference

Consolidated OpenCitations Corpus – April 2017